Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Analysis of KLLN as a high-penetrance breast cancer predisposition gene.

Thompson ER, Gorringe KL, Choong DY, Eccles DM; kConFab, Mitchell G, Campbell IG.

Breast Cancer Res Treat. 2012 Jul;134(2):543-7. doi: 10.1007/s10549-012-2088-3. Epub 2012 May 13.

PMID:
22580995
2.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
3.

Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.

Lindeman GJ, Hiew M, Visvader JE, Leary J, Field M, Gaff CL, Gardner RJ, Trainor K, Cheetham G, Suthers G, Kirk J.

Breast Cancer Res. 2004;6(4):R401-7. Epub 2004 Jun 2.

4.

Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.

Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F; INHERIT BRCAs.

J Hum Genet. 2009 Mar;54(3):152-61. doi: 10.1038/jhg.2009.6. Epub 2009 Feb 6.

PMID:
19197335
5.

Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.

Huo X, Hu Z, Zhai X, Wang Y, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wei Q, Wang X, Shen H.

Breast Cancer Res Treat. 2007 May;102(3):329-37. Epub 2006 Sep 21.

PMID:
17028982
6.

PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.

Kim JH, Choi DH, Cho DY, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2010 Jul;122(1):303-6. doi: 10.1007/s10549-010-0806-2. Epub 2010 Mar 6.

PMID:
20213081
7.

Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.

Pietschmann A, Mehdipour P, Mehdipour P, Atri M, Hofmann W, Hosseini-Asl SS, Scherneck S, Mundlos S, Peters H.

J Cancer Res Clin Oncol. 2005 Aug;131(8):552-8. Epub 2005 May 26.

PMID:
15918047
8.

Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.

Guénard F, Labrie Y, Ouellette G, Joly Beauparlant C, Simard J, Durocher F; INHERIT BRCAs.

J Hum Genet. 2008;53(7):579-91. doi: 10.1007/s10038-008-0285-z. Epub 2008 Apr 15.

PMID:
18414782
9.

Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.

Cao AY, Jin W, Shi PC, Di GH, Shen ZZ, Shao ZM.

Breast Cancer Res Treat. 2010 Jan;119(2):295-303. doi: 10.1007/s10549-009-0349-6. Epub 2009 Feb 24.

PMID:
19238535
10.

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.

BMC Cancer. 2006 Sep 29;6:230.

11.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.

Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN.

Breast Cancer Res Treat. 2008 Apr;108(3):399-408. Epub 2007 May 31.

PMID:
17541742
12.

BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.

Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, Benider A, Caligo MA.

Gynecol Oncol. 2012 Jun;125(3):687-92. doi: 10.1016/j.ygyno.2012.03.007. Epub 2012 Mar 13.

PMID:
22425665
13.

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.

Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG.

Breast Cancer Res Treat. 2008 Oct;111(3):505-9. Epub 2007 Oct 31.

PMID:
17972171
14.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.

Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.

Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.

PMID:
21562711
15.

Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.

Nizialek EA, Peterson C, Mester JL, Downes-Kelly E, Eng C.

Hum Mol Genet. 2013 Jun 15;22(12):2451-61. doi: 10.1093/hmg/ddt097. Epub 2013 Feb 27.

17.

Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.

Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P.

Breast Cancer Res Treat. 2010 Nov;124(2):337-47. doi: 10.1007/s10549-010-0745-y. Epub 2010 Feb 5.

PMID:
20135348
18.

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium.

Am J Hum Genet. 2003 Apr;72(4):1023-8. Epub 2003 Feb 27.

19.

A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.

De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA.

Clin Cancer Res. 2008 Jul 15;14(14):4672-80. doi: 10.1158/1078-0432.CCR-08-0087.

20.

Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

Johnson J, Healey S, Khanna KK; kConFab, Chenevix-Trench G.

Breast Cancer Res Treat. 2011 Aug;129(1):255-63. doi: 10.1007/s10549-011-1539-6. Epub 2011 Apr 28.

PMID:
21533530
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk